Thorac Cardiovasc Surg 2003; 51(2): 84-88
DOI: 10.1055/s-2003-38991
Original Cardiovascular
© Georg Thieme Verlag Stuttgart · New York

Antibiotic Prophylaxis in Elective Thoracic Surgery: Cefuroxime versus Cefepime

A.  Turna1 , C.  A.  Kutlu1 , T.  Ozalp1 , A.  Karamustafaoglu1 , L.  Mulazımoğlu2 , M.  A.  Bedirhan1
  • 1Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery, Department of Thoracic Surgery, Istanbul, Turkey
  • 2Marmara University. Department of Infectious Diseases, Istanbul, Turkey
Further Information

Publication History

Received: September 18, 2002

Publication Date:
05 May 2003 (online)

Abstract

Background: Infection is one of the major morbidity factors after thoracic surgery. Although different prophylactic regimens have been used to prevent this complication, the ideal prophylactic agent, dose and duration of administration remain unknown. Methods: All patients included underwent elective lung resection. 102 selected patients consecutively scheduled for major thoracic surgery were enrolled in this study and randomized into either the cefuroxime group (n = 50) or the cefepime group (n = 52). Results: Twelve pathologic bacterium strains were isolated in the cefepime group, whereas only 5 pathogenic strains were isolated in the cefuroxime group; the difference was statistically significant (p = 0.04). Two empyemas (3.8 %) in the cefepime group were noted, while the cefuroxime group showed no cases of empyema (p = 0.16). Overall infection rate (pneumonia + bronchopneumonia + empyema) were 14.0 % and 26.7 % in the cefuroxime and the cefepime groups, respectively (p = 0.12). Using chest radiography, pulmonary infiltration was found to be more frequent in the cefuroxime group (p=0.002). Conclusion: Cefuroxime as a prophylactic agent in major thoracic surgical operations was marginally more effective than cefepime, and presented an additional cost advantage.

References

  • 1 Fry W A. Thoracic Incisions. In T.W.Shields, ed General Thoracic Surgery. Philadelphia: Williams and Wilkins 1994: 381-391
  • 2 Bernard A, Pillet M, Goudet P, Viard H. Antibiotic prophylaxis in pulmonary surgery.  J Thorac Cardiovasc Surg. 1994;  107 896-900
  • 3 Aznar R, Mateu M, Miro J M, Gatell J M, Gimferrer J M, Aznar E. et al . Antibiotic prophylaxis in non-cardiac thoracic surgery: Cefazolin versus placebo.  Eur J Cardiotorac Surg. 1991;  5 (10) 515-518
  • 4 Weber D J, Raasch R, Rutala W A. Nosocomial Infections in the ICU. The growing importance of antibiotic-resistant pathogens.  Chest. 1999;  115 34S-41S
  • 5 Cameron J L, Imbembo A, Kieffer R F, Spray S, Baker R R. Prospective clinical trial of antibiotics for pulmonary resection.  Surg Gynecol Obstet. 1981;  152 156-158
  • 6 Ferdinand B, Shennib H. Postoperative pneumonia.  Chest Surg Clin N Am. 1998;  8 529-539
  • 7 Souney P F, Stoukides C A. Infectious Disease. In Shargel L, ed Pharmacy Review. Pennsylvania: Harwal Publishing 1989: 449-473
  • 8 Bruce D L, Wingard D N. Anaesthesia and the immune response.  Anesthesiology. 1971;  34 271-273
  • 9 Park S K, Brody J I, Wallace H. Immunosuppressive effect of surgery.  Lancet. 1971;  1 53-55
  • 10 Powers J H, Scheld W M. Cefepime: A new beta-lactamase-resistant broad spectrum cephalosporin.  Resident & Staff Physician. 1996;  6 46-52
  • 11 Sanders C C. Cefepime: The next generation.  Clin Inf Dis. 1993;  17 369-379
  • 12 Bernard G R, Artigas A, Brigham K L, Carlet J, Falke K, Hudson L. et al . The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.  Am J Crit Care Med. 1994;  149 818-824
  • 13 Anonymous . CDC definitions for nosocomial infections, 1988.  Am Rev Respir Dis. 2001;  139 1058-1059
  • 14 Gunseren F, Mamikoglu L, Ozturk S, Yucesoy M, Biberoglu K, Yulug N. et al . A surveillance of antimicrobial resistance of Gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey.  J Antimicrob Chemother. 1999;  43 373-378
  • 15 Slack M P. Antimicrobial Chemotherapy. In.Weatheral DJ, Ledingham JGG, Warrel DA, eds. Oxford Textbook of Medicine. Oxford: Oxford University Press 1988: 5.35-5.53
  • 16 Truesdale R, D'Alessandri R, Manuel V, Daicoff G, Kluge R M. Antimicrobial vs placebo prophylaxis in noncardiac thoracic surgery.  JAMA. 1979;  241 1254-1256
  • 17 Spain D A. Pneumonia in the surgical patient: Duration of therapy and does organism matter?.  Am J Surg. 2000;  179 36S-40S
  • 18 Walker W S, Faichney A, Raychaudhury T. Wound prophylaxis in thoracic surgery: new approach.  Thorax. 1984;  39 121-124
  • 19 Cunha B A, Gill M V. Cefepime.  Med Clin North Am. 1995;  79 721-732

Dr. Akif Turna

Cami Sok.

Muminderesi Yolu. No: 32/22

Sahrayicedid. Kadikoy

81080 Istanbul

Turkey

Phone: +90/216/4113675

Fax: +90/212/4116651

Email: aturna@turk.net

    >